Mycophenolic Acid

• 

  Subject Areas on Research

  • A novel approach to the treatment of chronic allograft nephropathy. 
  • A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 
  • A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 
  • A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. 
  • A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. 
  • A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. 
  • Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. 
  • Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism. 
  • Advances in pancreas transplantation: the University of Wisconsin experience. 
  • Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. 
  • An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. 
  • Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. 
  • Aplastic anaemia as an autoimmune complication of thymoma. 
  • Bullous systemic lupus erythematosus in a 6-year-old boy. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. 
  • Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. 
  • Clinical trial of focal segmental glomerulosclerosis in children and young adults. 
  • Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. 
  • Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 
  • Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. 
  • Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 
  • Conversion from mycophenolate mofetil to azathioprine in renal allograft [corrected] patients within the first month posttransplantation. 
  • Current therapies for lupus nephritis in an ethnically heterogeneous cohort. 
  • Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. 
  • Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. 
  • Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. 
  • Effects of Immunosuppressive Medications on Mitochondrial Function. 
  • Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network database. 
  • Experience with 500 simultaneous pancreas-kidney transplants. 
  • First-Principles Molecular Structure Search with a Genetic Algorithm. 
  • Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids. 
  • Guidance for liver transplant immunosuppression. 
  • Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. 
  • Improvement of multiple sclerosis on tacrolimus plus mycophenolate mofetil after liver transplantation. Clinical improvement of multiple sclerosis in a patient requiring liver transplantation for acute liver failure following interferon-beta therapy. 
  • Interleukin-15 receptor blockade in non-human primate kidney transplantation. 
  • Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. 
  • Lessons from two trials of mycophenolate mofetil in myasthenia gravis. 
  • Living unrelated kidney donation: an underutilized resource? 
  • Management of childhood onset nephrotic syndrome. 
  • Management of patients with confirmed and presumed mucous membrane pemphigoid undergoing entropion repair. 
  • Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. 
  • Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. 
  • Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. 
  • Mycophenolate mofetil in myasthenia gravis: the unanswered question. 
  • Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. 
  • Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. 
  • Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. 
  • Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 
  • Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. 
  • Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. 
  • Reversal of acute allograft rejection using immunotoxin. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. 
  • Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. 
  • T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. 
  • Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. 
  • Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 
  • The influence of RS-61443 on antibody-mediated rejection. 
  • The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. 
  • Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. 
  • Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. 
  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 
  • Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States. 
  • Update on new immunomodulatory agents. 
  • Vasculitis and Pregnancy. 
  • [IgA pemphigus. Successful treatment with mycophenolate mofetil]. 
• 

  Keywords of People

  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology